206 related articles for article (PubMed ID: 29526637)
1. Clinical and experimental evidence for targeting CD6 in immune-based disorders.
Consuegra-Fernández M; Lin F; Fox DA; Lozano F
Autoimmun Rev; 2018 May; 17(5):493-503. PubMed ID: 29526637
[TBL] [Abstract][Full Text] [Related]
2. CD318 is a ligand for CD6.
Enyindah-Asonye G; Li Y; Ruth JH; Spassov DS; Hebron KE; Zijlstra A; Moasser MM; Wang B; Singer NG; Cui H; Ohara RA; Rasmussen SM; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6912-E6921. PubMed ID: 28760953
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD6 mAbs for the treatment of psoriasis.
Dogra S; D S; Rajagopalan M
Expert Opin Biol Ther; 2020 Oct; 20(10):1215-1222. PubMed ID: 32466689
[TBL] [Abstract][Full Text] [Related]
4. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.
Gurrea-Rubio M; Wu Q; Amin MA; Tsou PS; Campbell PL; Amarista CI; Ikari Y; Brodie WD; Mattichak MN; Muraoka S; Randon PM; Lind ME; Ruth JH; Mao-Draayer Y; Ding S; Shen X; Cooney LA; Lin F; Fox DA
Cancer Immunol Immunother; 2024 Jan; 73(2):34. PubMed ID: 38280067
[TBL] [Abstract][Full Text] [Related]
5. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y
Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060
[TBL] [Abstract][Full Text] [Related]
6. CD6 as a potential target for treating multiple sclerosis.
Li Y; Singer NG; Whitbred J; Bowen MA; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2687-2692. PubMed ID: 28209777
[TBL] [Abstract][Full Text] [Related]
7. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U; Saha A; Kuriakose A; Nair R; Sadashivarao RB; Venkataraman R; Patel S; Deshchougule AT; S SK; Montero E; Pai HV; Palanivelu DV; Melarkode R; Nair P
PLoS One; 2017; 12(7):e0180088. PubMed ID: 28672038
[TBL] [Abstract][Full Text] [Related]
8. Domain-specific CD6 monoclonal antibodies identify CD6 isoforms generated by alternative-splicing.
Santos RF; Oliveira L; Brown MH; Carmo AM
Immunology; 2019 Aug; 157(4):296-303. PubMed ID: 31162836
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.
Hernández P; Moreno E; Aira LE; Rodríguez PC
Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560
[TBL] [Abstract][Full Text] [Related]
10. CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action.
Garner LI; Hartland A; Breuning J; Brown MH
Immunology; 2018 Oct; 155(2):273-282. PubMed ID: 29772075
[TBL] [Abstract][Full Text] [Related]
11. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis.
Dogra S; Uprety S; Suresh SH
Expert Opin Biol Ther; 2017 Mar; 17(3):395-402. PubMed ID: 28064543
[TBL] [Abstract][Full Text] [Related]
12. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor.
Ibáñez A; Sarrias MR; Farnós M; Gimferrer I; Serra-Pagès C; Vives J; Lozano F
J Immunol; 2006 Jul; 177(2):1152-9. PubMed ID: 16818773
[TBL] [Abstract][Full Text] [Related]
13. Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes.
Singer NG; Richardson BC; Powers D; Hooper F; Lialios F; Endres J; Bott CM; Fox DA
Immunology; 1996 Aug; 88(4):537-43. PubMed ID: 8881754
[TBL] [Abstract][Full Text] [Related]
14. T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1.
da Glória VG; Martins de Araújo M; Mafalda Santos A; Leal R; de Almeida SF; Carmo AM; Moreira A
J Immunol; 2014 Jul; 193(1):391-9. PubMed ID: 24890719
[TBL] [Abstract][Full Text] [Related]
15. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody.
Alonso R; Huerta V; de Leon J; Piedra P; Puchades Y; Guirola O; Chinea G; Montero E
Hybridoma (Larchmt); 2008 Aug; 27(4):291-301. PubMed ID: 18707547
[TBL] [Abstract][Full Text] [Related]
16. Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction.
Starling GC; Whitney GS; Siadak AW; Llewellyn MB; Bowen MA; Farr AG; Aruffo AA
Eur J Immunol; 1996 Apr; 26(4):738-46. PubMed ID: 8625962
[TBL] [Abstract][Full Text] [Related]
17. The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.
Chalmers SA; Ayilam Ramachandran R; Garcia SJ; Der E; Herlitz L; Ampudia J; Chu D; Jordan N; Zhang T; Parodis I; Gunnarsson I; Ding H; Shen N; Petri M; Mok CC; Saxena R; Polu KR; Connelly S; Ng CT; Mohan C; Putterman C
J Clin Invest; 2022 Jan; 132(1):. PubMed ID: 34981775
[TBL] [Abstract][Full Text] [Related]
18. CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies.
Aragón-Serrano L; Carrillo-Serradell L; Planells-Romeo V; Isamat M; Velasco-de Andrés M; Lozano F
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139340
[TBL] [Abstract][Full Text] [Related]
19. CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
Pinto M; Carmo AM
BioDrugs; 2013 Jun; 27(3):191-202. PubMed ID: 23568178
[TBL] [Abstract][Full Text] [Related]
20. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells.
Zimmerman AW; Joosten B; Torensma R; Parnes JR; van Leeuwen FN; Figdor CG
Blood; 2006 Apr; 107(8):3212-20. PubMed ID: 16352806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
